$6mil Centre Grant over 2 years, funded by National Medical Research Council
Contact Details:
Aims and Research Themes
The overall research programme in the newly established Cardiovascular Research Institute (CVRI) aims to develop a translational programme of research reaching from laboratory to clinic and community by integrated efforts from clinician-researchers undertaking large scale clinical cohort studies and smaller detailed mechanistic sub-studies linked with basic scientists developing related animal models and biomarkers. Projects are focused upon the cardinal cardiovascular diseases including acute coronary disease, acute and chronic heart failure (and its substrate conditions) and cardiac valve (mitral regurgitation and aortic valve stenosis) disease.
Current and proposed projects address clarification of the prevalence, outcomes and pathophysiology of these disorders and tests potential improvements in management. The programme is under-pinned by discovery and testing of new biomarkers with the potential to improve our understanding of the natural history and underlying pathophysiology of heart failure with and without preserved ejection fraction and with and without concurrent renal impairment; in earlier detection of evolving cardiac ischemia or acute cardiac decompensation; and in improved projection of progression of valve disease to enhance timing and efficacy of established and novel interventions.
The five umbrella themes are:
- Heart failure: Potential utility of new candidate biomarkers for diagnosis and prognosis in the patient with recent offset breathlessness
- Heart failure with preserved ejection fraction (HF-PEF)
- Management of Cardiac Valve Disease
- Acute Coronary Syndrome
- Ventricular Repair
Selected Publications
Wright SP, Doughty RN, Frampton CM, Gamble GD, Yandle TG, Richards AM. Plasma Urocortin 1 in Human Heart Failure Circulation 2009 (in press)
Palmer SC, Yandle TG, Framptom CM, Troughton RW, Nicholls MG, Richards AM Renal and Cardiac Function for Long Term (10year) Risk Stratification after Myocardial Infarction Eur Heart Journal (In press) 2009.
Lainchbury JG, Troughton RW, Strangman KM, Frampton CM, Pilbrow A, Yandle TG, Hamid KH, Nicholls MG, Richards AM NTproBNP-guided Treatment for Chronic Heart Failure: results from the BATTLESCARRED trial J Am Coll Cardiol (in press) 2009.
Palmer BR, Pilbrow AP, Frampton CM, Yandle TG, Skelton L, Nicholls MG, Richards AM Plasma Aldosterone Levels During Hospitalization are Predictive of Survival Post-Myocardial Infarction Eur Heart J 2008; 29(20):2489-96.
Molyneux S, Florkowski CM, George PM, Pilbrow AP, Frampton CM, Lever M, Richards AM Coenzyme Q10: an independent predictor of mortality in chronic heart failure J Am Coll Cardiol 2008;52:1435-41.
Davis ME, Pemberton CP, Yandle TG, Fisher SF, Lainchbury JG, Frampton CM, Rademaker MT, Richards AM Urocortin 2 infusion in human heart failure Eur Heart J 2007; 28:2589-2597.
Richards AM, Nicholls MG, Espiner EA, Lainchbury JG, Troughton RW, Elliott J, Frampton CM, Crozier IG, Yandle TG, Doughty R, Macmahon S, Sharpe N. Comparison of B-type natriuretic peptides for assessment of cardiac function and prognosis in stable ischemic heart disease. J Am Coll Cardiol 2006; 47:52-60.
Januzzi JL, Van Kimmenade R, Lainchbury J, Bayes-Genis A, Ordonez-Llanos J, Santalo-Bei M, Pinto Y, Richards AM. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients. The International Collaborative of NT-proBNP (ICON) Study. Eur Heart J 2006; 27:330-337.
Rademaker MT, Cameron VA, Charles CJ, Richards AM. Integrated hemodynamic, hormonal and renal actions of urocortin 2 in normal and paced sheep: beneficial effects in heart failure. Circulation 2005;112:3624-3632.
Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma amino terminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000; 355:1126-1130.
